随着甲状腺乳头状癌病例逐渐增多和甲状腺癌相对较好的预后，其临床治疗方案也逐渐多样化，可以根据肿瘤的恶性程度和患者的意愿选择不同的治疗方法，如手术、局部消融或随访观察。其中术前评估甲状腺乳头状癌的恶性程度侵袭潜能是选择治疗方案中重要的一个环节。术前US-FNA能够获取患者的肿瘤细胞，通过对其进行分子检测，可以提高诊断准确性并预测预后，但目前并没有一个分子能够对淋巴结转移风险进行准确的评估。在前期实验的基础上，我们发现HMGA2在甲状腺癌中高表达，且发生颈部淋巴结转移的病例表达量明显高于未转移的病例，其对甲状腺癌侵袭性的影响文献尚未鲜见报道，本课题组打算进一步研究HMGA2在甲状腺微小乳头状癌中促进肿瘤侵袭转移的价值，探讨是否可以利FNA中获取的细胞进行HMAG2检测从而预测发生颈部淋巴结转移的风险，从而为临床选择治疗方案提供有力的证据。

Incidence of papillary thyroid carcinoma has been increasing every year but however, most of them have good prognosis which bring more options of treatment when patients have being diagnosed as thyroid cancer such as surgery, ablation, or just observing. To choose which option suits best for each patient, it is very important to evaluate the malignancy potential before histological analysis which is usually obtained after surgery. Pre-operative fine needle aspiration (FNA) has been used extensively to diagnose thyroid nodules and molecular array will help it to diagnose more accurately. However, there are no molecular can help predict the risk of the cervical lymph nodes metastasis. In our previous study, we found thyroid cancer with cervical lymph node metastasis express more HMGA2 than those without metastasis and it hasn’t been published before. So we boldly assume that if HMGA2 could be a sensitive indicator to predict the risk of metastasis in papillary thyroid carcinoma. So we intend to investigate how HMGA2 promote the metastasis and then investigate how to use it on cell samples obtained in FNA. Finally it may provide information for clinical consideration of treatment.